Ryplazim Injection, Powder, Lyophilized, For Solution
Product Images NDC 70573-099
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Ryplazim (NDC 70573-099). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Kedrion Biopharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 2 (Ryplazim 02)
Figure 3 (Ryplazim 03)
Figure 4 (Ryplazim 04)
Fig A (Ryplazim 05)
Fig B (Ryplazim 06)
Fig C (Ryplazim 07)
Fig D (Ryplazim 08)
Principal Display Panel (68.8 mg Vial Label)
This is a description of Ryplazim®, a human plasminogen used for intravenous use only. The medicine is stored at 2-25 °C and each vial contains 68.8 mg of human plasminogen which is reconstituted in 12.5 ml of sterile water for injection. Ryplazim® is manufactured for Prometic Biotherapeutics, Inc located in Fort Lee, New Jersey, USA by Prometc Bioproducton, Inc located in Laval, Quebec, Canada. Any unused portion should be discarded. A prescription is necessary for purchase.*
Principal Display Panel (68.8 mg Vial Carton)
Ryplazim is a single-dose vial containing 68.8mg human plasminogen that is intended for intravenous use only. The vial must be stored at room temperature and should not be frozen. It is a sterile, preservative-free medicine. Any unused portion should be discarded. The manufacturer is Prometic and the product is produced in Canada and the USA. The medication has a national drug code of 7057309902.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.